Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On
In accordance with Nasdaq's Listing Rule 5605(c)(4) ("the "Rule"), Nasdaq
provides a cure period in order to regain compliance. The cure period is until
the earlier of the Company's next annual shareholders' meeting or
The Company must submit documentation, including the biography of any new director, evidencing compliance of the Rule no later than the compliance date described above. The Company is working diligently to comply with Nasdaq's audit committee requirements as set for in the Rule within the cure period provided by Nasdaq, and expects to evidence compliance to Nasdaq no later than the compliance date.
--------------------------------------------------------------------------------
© Edgar Online, source